vimarsana.com

Page 82 - தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |CTS Eventim AG & Co KGaA Announcements | CTS Eventim AG & Co KGaA: CTS EVENTIM signs joint venture with Zappa to become Israel s ticketing marketing leader

CTS EVENTIM signs joint venture with Zappa to become Israel s ticketing marketing leader DGAP-News: CTS Eventim AG & Co. KGaA / Key word(s): Joint Venture CTS EVENTIM signs joint venture with Zappa to become Israel s ticketing marketing leader 18.02.2021 / 15:00 Press Release CTS EVENTIM signs joint venture with Zappa to become Israel s ticketing marketing leader Munich/Tel Aviv, 18 February 2021. CTS EVENTIM, one of the leading international providers of ticketing services and live entertainment, is expanding its business operations in Israel and, by signing a joint venture with the Zappa Group, is taking the lead in the country s ticketing market. The Zappa Group is the most important local promoter of live events, including a dozen popular festivals, and operates venues in Israel that seat up to 15,000. The partnership gives Zappa access to CTS EVENTIM s wide range of eCommerce marketing tools and powerful technologies, such as data analytics or the web shop for ticket sa

VARTA AG: VARTA AG exceeds guidance, announces first-ever dividend payments and presents new brand identity

VARTA AG: VARTA AG exceeds guidance, announces first-ever dividend payments and presents new brand identity 18.02.2021 / 07:00   VARTA AG exceeds guidance, announces first-ever dividend payments and presents new brand identity Highly dynamic growth of around 140% in Group revenue to approximately ? 870m   Adjusted EBITDA rises by roughly 145% to approximately ? 239m Adjusted EBITDA margin improves to around 27.5% Microbatteries & Solutions records very strong fiscal year performance Very positive development in the Household Batteries segment   Start of dividend payments: roughly ? 100m to be paid out Promising outlook for 2021: organic growth in revenue and profit again on the cards for fiscal year 2021 Audited financial statements for 2020 to be published on 31

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002

Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today an amendment of the agreement with Vyera Pharmaceuticals AG for the development of SLS-002 to repurchase in cash a significant portion of the royalties payable on any future net sales of SLS-002. On March 6, 2018 Seelos entered into an .

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.